LOC340094 inhibitors represent a specialized chemical class developed to selectively target and modulate the function of the non-coding RNA LOC340094. As a member of the extensive family of non-coding RNAs, LOC340094 is categorized as a long intergenic non-protein coding RNA (lincRNA). Despite its lack of protein-coding capacity, lincRNAs have emerged as essential regulators of diverse cellular processes. The inhibitors designed for LOC340094 are intricately crafted to interact with the specific molecular structure of this non-coding RNA, with the primary aim of disrupting its normal interactions within the cellular environment and potentially influencing various cellular regulatory networks.
The molecular architecture of LOC340094 inhibitors is meticulously tailored to engage specific binding sites on the RNA molecule, inducing changes in its conformation and dynamics. This interaction holds the potential to impact the regulatory functions that LOC340094 may exert in cellular processes. In laboratory research, these inhibitors serve as crucial tools, enabling scientists to dissect the nuanced functions of LOC340094 in various cellular contexts. By manipulating the function of LOC340094, researchers aim to unravel the complex mechanisms of non-coding RNA-mediated regulation, contributing to a deeper understanding of the intricate network of molecular players orchestrating cellular processes and potential roles in cellular homeostasis. The study of LOC340094 inhibitors stands at the forefront of advancing our comprehension of non-coding RNA biology and the nuanced roles these molecules play in the intricate web of cellular regulatory mechanisms.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $196.00 | 9 | |
As a histone deacetylase inhibitor, it can alter chromatin structure, potentially downregulating lncRNA expression. | ||||||
EPZ6438 | 1403254-99-8 | sc-507456 | 1 mg | $66.00 | ||
An EZH2 inhibitor that can affect histone methylation, potentially altering the transcription of genes including lncRNAs. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $116.00 $330.00 $510.00 $816.00 $1632.00 | 10 | |
By targeting BCL-2, it may indirectly affect transcriptional programs, potentially impacting lncRNA levels. | ||||||
Pladienolide B | 445493-23-2 | sc-391691 sc-391691B sc-391691A sc-391691C sc-391691D sc-391691E | 0.5 mg 10 mg 20 mg 50 mg 100 mg 5 mg | $290.00 $5572.00 $10815.00 $25000.00 $65000.00 $2781.00 | 63 | |
A spliceosome inhibitor that could disrupt mRNA splicing and impact lncRNA processing and expression. | ||||||
I-BET 151 Hydrochloride | 1300031-49-5 (non HCl Salt) | sc-391115 | 10 mg | $450.00 | 2 | |
A BET bromodomain inhibitor that affects the expression of genes by altering chromatin, potentially influencing lncRNA transcription. | ||||||
GSK126 | 1346574-57-9 | sc-490133 sc-490133A sc-490133B | 1 mg 5 mg 10 mg | $90.00 $238.00 $300.00 | ||
Inhibits EZH2, which may result in broad changes in gene expression, including effects on lncRNA transcription. | ||||||
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $260.00 $925.00 | 5 | |
A competitive inhibitor of p300/CBP histone acetyltransferase, potentially changing expression patterns of lncRNAs. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $128.00 $505.00 | 2 | |
A DNA methyltransferase inhibitor, which could lead to changes in the methylation status of genes, affecting lncRNA expression. | ||||||